Raritan: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally ...

Endocytosis and recycling control the uptake and retrieval of various materials in eukaryotic cells. Mammalian cells have ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

Black women in the US have a significantly higher risk of breast cancer mortality across all subtypes, with disparities ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

The US Food and Drug Administration yesterday approved a new indication for Rybrevant (amivantamab-vmjw), from Johnson & ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

Johnson & Johnson said the Food and Drug Administration approved its treatment of locally-advanced or metastatic non-small cell lung cancer for adults. The treatment, called Rybrevant, has been ...